News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
09 28 2017 Analysis of Quest Diagnostics prescription drug monitoring data also found that for more than half of results with concurrent use, one drug had been prescribed by a physician and one had not, suggesting potentially dangerous drug combinations without a physician's oversightMore than 25 percent of patients monitored by lab tests for prescription drug adherence are concurrently taking both opioids and benzodiazepines, according to a new study published online today in...
-
09 27 2017 Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the third quarter of 2017 it expects a reduction in revenues...
-
09 22 2017 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, responded today to the Centers for Medicare and Medicaid Services (CMS) publication of proposed 2018...
-
09 14 2017 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, was named for the thirteenth consecutive year in the North America Dow Jones Sustainability Index...
-
09 07 2017 Quest is first national diagnostic services provider to use novel LDL-cholesterol calculation that improves accuracy of heart disease screening and helps personalize treatment with lipid-lowering medications such as PCSK9 inhibitors and statinsQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that all of the company's cholesterol test services that involve estimates of...
09 06 2017 Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare...
09 06 2017 New examination of 3.4 million drug monitoring lab results shows wide evidence of dangerous drug combinations, including opioids/benzodiazepines and heroin/fentanylA majority of test results of patients taking prescription medications show signs of drug misuse, including potentially dangerous drug combinations, finds a new large-scale analysis of laboratory...
-
08 18 2017 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.45 per share,...
-
07 25 2017 - Second quarter revenues of $1.94 billion, up 1.9% on a reported basis and up 2.3% on an equivalent basis versus 2016.Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2017 and raised...
07 19 2017 QHerit Expanded Carrier Screen helps both women and men across multiple ethnicities identify risk of passing 22 genetic diseases to their childrenQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of QHerit™, a new genetic screening service that provides women and men...